MAP1B and neoplasm: Functional enrichment (GSVA, GSEA), tumor microenvironment estimation (ESTIMATE, ssGSEA), drug sensitivity prediction (GDSC2), and in vitro experiments were performed to characterize the biological and therapeutic relevance of PRGS, with MAP1B selected for experimental validation.